	US 12,303,522 B2
	Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a gabaergic function in the central nervous system
Jonas Hauser, Lausanne (CH); and Jian Yan, Seattle, WA (US)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 17/255,013
Filed by SOCIETE DES PRODUITS NESTLE S.A., Vevey (CH)
PCT Filed May 21, 2019, PCT No. PCT/EP2019/063035 § 371(c)(1), (2) Date Dec. 22, 2020, PCT Pub. No. WO2020/001863, PCT Pub. Date Jan. 2, 2020.
Claims priority of provisional application 62/689,297, filed on Jun. 25, 2018.
Prior Publication US 2021/0268005 A1, Sep. 2, 2021
Int. Cl. A61K 31/702 (2006.01); A23K 10/18 (2016.01); A23K 20/163 (2016.01); A23L 33/00 (2016.01); A23L 33/135 (2016.01)

CPC A61K 31/702 (2013.01) [A23K 10/18 (2016.05); A23K 20/163 (2016.05); A23L 33/135 (2016.08); A23L 33/40 (2016.08)]

11 Claims

1. A method for improving, enhancing, promoting or modulating a) a GABAergic function in the central nervous system (CNS) or b) filtering of information or the capacity to focus or concentrate on a mental or physical activity in a mammal suffering from a health status or disease related to GABAergic function, the method comprising:

administering a nutritional composition comprising an effective amount of a combination of a bovine milk oligosaccharide (BMO) and a human milk oligosaccharide (HMO) to the mammal suffering from the health status or disease related to GABAergic function,

wherein the HMO comprises a combination of 2′fucosyllactose (2FL) and lacto-N-neotetraose (LNnT).